“Our first-quarter sales growth is in line with our objectives,” commented Stéphane Bancel, bioMérieux’s chief executive officer. “In today’s difficult financial and economic climate, our product diversification, our
Novagali Pharma, a France-based ophthalmic pharmaceutical company, has successfully completed a new Phase II clinical study with Cyclokat, its formulation of cyclosporine. The results demonstrate statistically significant improvement
Medicure, a biopharmaceutical company engaged in the research, development and commercialization of novel small molecules to treat cardiovascular and neurological disorders, has reported a net loss of C$3.64m,
Dendreon has enrolled the first patient in a Phase I clinical trial of D3263 in patients with advanced cancer. D3263 is the company’s lead small molecule drug candidate
Before joining Sloning, Mr Merry has held several executive positions in the field of sales and marketing with companies such as Applied Biosystems, Millipore, or Qiagen, where he
Circassia has initiated a Phase II clinical study of its ToleroMune technology in allergy patients with asthma. The trial builds on positive Phase II results that demonstrated the
Under the terms of the agreement, DTL will market the Sonablate 500 high intensity focused ultrasound (HIFU) system as a mobile, ‘fee for use’ service to hospitals in
The agreement was entered into to advance the development of NovaBay’s Aganocide compounds by integrating extensive and ongoing clinical work at the university with NovaBay’s development program. Under
Nymox Pharmaceutical has received the investigational review board’s approval to begin NX02-0017, the first Phase III US clinical trial for NX-1207, the company’s investigational drug for benign prostatic
Waban, headquartered in Cambridge, Massachusetts, and with operations in Mumbai, India, will become the Waban Software Group within Phase Forward. The Waban Software acquisition extends Phase Forward’s portfolio
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.